Tags : Multiple studies

Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in

Shots: The presentation includes a collective analysis of 10 research abstracts plus results of OSLER-1 study, assessing Repatha (evolocumab) (420mg) in hypercholesterolemia patients for up to 5 yrs. & an additional RWE of FOURIER study assessing triglycerides in patients with CV risk FOURIER P-III (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated […]Read More